Literature DB >> 18505252

Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells.

Mary K O'Reilly1, Brian E Collins, Shoufa Han, Liang Liao, Cory Rillahan, Pavel I Kitov, David R Bundle, James C Paulson.   

Abstract

CD22 is a B cell-specific sialic acid-binding immunoglobulin-like lectin (Siglec) whose function as a regulator of B cell signaling is modulated by its interaction with glycan ligands bearing the sequence NeuAc alpha2-6Gal. To date, only highly multivalent polymeric ligands (n = 450) have achieved sufficient avidity to bind to CD22 on native B cells. Here we demonstrate that a synthetic bifunctional molecule comprising a ligand of CD22 linked to an antigen (nitrophenol; NP) can use a monoclonal anti-NP IgM as a decavalent protein scaffold to efficiently drive assembly of IgM-CD22 complexes on the surface of native B cells. Surprisingly, anti-NP antibodies of lower valency, IgA (n = 4) and IgG (n = 2), were also found to drive complex formation, though with lower avidity. Ligands bearing alternate linkers of variable length and structure were constructed to establish the importance of a minimal length requirement, and versatility in the structural requirement. We show that the ligand drives assembly of IgM complexes exclusively on the surface of B cells and not other classes of white blood cells that do not express CD22, which lends itself to the possibility of targeting B cells in certain hematopoietic malignancies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505252      PMCID: PMC2574768          DOI: 10.1021/ja802008q

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  41 in total

1.  UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation.

Authors:  O T Keppler; S Hinderlich; J Langner; R Schwartz-Albiez; W Reutter; M Pawlita
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 2.  Cell surface biology mediated by low affinity multivalent protein-glycan interactions.

Authors:  Brian E Collins; James C Paulson
Journal:  Curr Opin Chem Biol       Date:  2004-12       Impact factor: 8.822

Review 3.  B cells move to centre stage: novel opportunities for autoimmune disease treatment.

Authors:  Jeffrey L Browning
Journal:  Nat Rev Drug Discov       Date:  2006-07       Impact factor: 84.694

Review 4.  Siglecs--the major subfamily of I-type lectins.

Authors:  Ajit Varki; Takashi Angata
Journal:  Glycobiology       Date:  2005-07-13       Impact factor: 4.313

5.  Development of humanized antibodies as cancer therapeutics.

Authors:  Zhengxing Qu; Gary L Griffiths; William A Wegener; Chien-Hsing Chang; Serengulam V Govindan; Ivan D Horak; Hans J Hansen; David M Goldenberg
Journal:  Methods       Date:  2005-05       Impact factor: 3.608

6.  Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders.

Authors:  G D'Arena; P Musto; N Cascavilla; M Dell'Olio; N Di Renzo; M Carotenuto
Journal:  Am J Hematol       Date:  2000-08       Impact factor: 10.047

7.  Efficient preparation of natural and synthetic galactosides with a recombinant beta-1,4-galactosyltransferase-/UDP-4'-gal epimerase fusion protein.

Authors:  O Blixt; J Brown; M J Schur; W Wakarchuk; J C Paulson
Journal:  J Org Chem       Date:  2001-04-06       Impact factor: 4.354

Review 8.  Sweet spots in functional glycomics.

Authors:  James C Paulson; Ola Blixt; Brian E Collins
Journal:  Nat Chem Biol       Date:  2006-05       Impact factor: 15.040

9.  On-virus construction of polyvalent glycan ligands for cell-surface receptors.

Authors:  Eiton Kaltgrad; Mary K O'Reilly; Liang Liao; Shoufa Han; James C Paulson; M G Finn
Journal:  J Am Chem Soc       Date:  2008-03-15       Impact factor: 15.419

10.  Mannosyl glycodendritic structure inhibits DC-SIGN-mediated Ebola virus infection in cis and in trans.

Authors:  Fátima Lasala; Eva Arce; Joaquín R Otero; Javier Rojo; Rafael Delgado
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more
  28 in total

1.  CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

Authors:  Mary K O'Reilly; Hua Tian; James C Paulson
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

2.  A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Authors:  Andrew X Zhang; Ryan P Murelli; Cyril Barinka; Julien Michel; Alexandra Cocleaza; William L Jorgensen; Jacek Lubkowski; David A Spiegel
Journal:  J Am Chem Soc       Date:  2010-09-15       Impact factor: 15.419

Review 3.  Siglecs as sensors of self in innate and adaptive immune responses.

Authors:  James C Paulson; Matthew S Macauley; Norihito Kawasaki
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

4.  Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation.

Authors:  Adam H Courtney; Erik B Puffer; Jason K Pontrello; Zhi-Qiang Yang; Laura L Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

5.  In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins.

Authors:  Pavel I Kitov; George L Mulvey; Thomas P Griener; Tomasz Lipinski; Dmitry Solomon; Eugenia Paszkiewicz; Jared M Jacobson; Joanna M Sadowska; Missao Suzuki; Ken-Ichi Yamamura; Glen D Armstrong; David R Bundle
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

Review 6.  Endoglycosidases for the Synthesis of Polysaccharides and Glycoconjugates.

Authors:  Chao Li; Lai-Xi Wang
Journal:  Adv Carbohydr Chem Biochem       Date:  2016-08-23       Impact factor: 12.200

Review 7.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

8.  Click and pick: identification of sialoside analogues for siglec-based cell targeting.

Authors:  Cory D Rillahan; Erik Schwartz; Ryan McBride; Valery V Fokin; James C Paulson
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-04       Impact factor: 15.336

Review 9.  Siglecs as targets for therapy in immune-cell-mediated disease.

Authors:  Mary K O'Reilly; James C Paulson
Journal:  Trends Pharmacol Sci       Date:  2009-04-07       Impact factor: 14.819

Review 10.  Glycopolymer probes of signal transduction.

Authors:  Laura L Kiessling; Joseph C Grim
Journal:  Chem Soc Rev       Date:  2013-04-18       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.